A multicenter characterization of hepatitis associated with immune checkpoint inhibitors

References

• Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schandendorf D, Wagstaff J, Dummer R, et al. 2019. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. New England Journal of Medicine. 381(16):1535–7. doi:10.1056/NEJMoa1910836.
   PubMed Web of Science ®Google Scholar
• Weber JS, Hodi FS, Wolchok JD, Topalian SL, Schadendorf D, Larkin J, Sznol M, Long GV, Li H, Waxman IM, et al. 2017. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol. 35(7):785–792. doi:10.1200/JCO.2015.66.1389.
   PubMed Web of Science ®Google Scholar
• Patrinely JR, Young AC, Quach H, William GR, Ye F, Fan R, Horn L, Beckermann KE, Gillaspie EA, Sosman, JA, et al. 2020. Survivorship in immune therapy: assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand. Eur J Cancer. 135:211–220. doi:10.1016/j.ejca.2020.05.005.
   PubMed Web of Science ®Google Scholar
• Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L, et al. 2018. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 4(12):1721–1728. doi:10.1001/jamaoncol.2018.3923.
   PubMed Web of Science ®Google Scholar
• Naidoo J, Wang X, Woo KM, Iyriboz T, Halpenny D, Cunnigham J, Chaft JE, Segal NH, Callahan MK, Lesokhin AM, et al. 2017. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. J Clin Oncol. 35(7):709–717. doi:10.1200/JCO.2016.68.2005.
   PubMed Web of Science ®Google Scholar
• Abu-Sbeih H, Ali FS, Naqash AR, Owen DH, Patel S, Otterson GA, Kendra K, Ricciuti B, Chiari R, De Griglio A, et al. 2019. Resumption of immune checkpoint inhibitor therapy after immune-mediated colitis. J Clin Oncol. 37(30):2738–2745. doi:10.1200/JCO.19.00320.
   PubMed Web of Science ®Google Scholar
• Abu-Sbeih H, Herrera LN, Tang T, Chaftari AP, Okhuysen PC, Jeng RR, Wang Y. 2019. Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis. J Immunother Cancer. 7(1):242. doi:10.1186/s40425-019-0714-x.
   PubMed Web of Science ®Google Scholar
• Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB. 2018. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet. 391(10124):933. doi:10.1016/S0140-6736(18)30533-6.
   PubMed Web of Science ®Google Scholar
• Wang DY, Mooradian MJ, Kim D, Shah NJ, Fenton SE, Conry RM, Mehta R, Silk AW, Zhou A, Compton ML, et al. 2019. Clinical characterization of colitis arising from anti-PD-1 based therapy. Oncoimmunology. 8(1):e1524695. doi:10.1080/2162402X.2018.1524695.
   PubMed Web of Science ®Google Scholar
• Mahmood SS, Fradley MG, Cohen JV, Nohria A, Reynolds KL, Heinzerling KL, Sullivan RJ, Damrongwatanasuk R, Chen CL, Gupta D, et al. 2018. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol. 71(16):1755–1764. doi:10.1016/j.jacc.2018.02.037.
   PubMed Web of Science ®Google Scholar
• Thompson JA, Schneider BJ, Brahmer J, Andrew S, Armand P, Bhatia S, Budde LE, Costa L, Davies M, Dunnington D, et al. 2020. NCCN guidelines insights: management of immunotherapy-related toxicities, version 1.2020. J Natl Compr Canc Netw. 18(3):230–241. doi:10.6004/jnccn.2020.0012.
   PubMed Web of Science ®Google Scholar
• Puzanov I, Diab A, Abdallah K, Bingham CO, Brogdon C, Dadu R, Hamad L, Kim S, Lacouture ME, LeBoeuf NR, et al. 2017. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) toxicity management working group. J Immunother Cancer. 5(1):95. doi:10.1186/s40425-017-0300-z.
   PubMed Web of Science ®Google Scholar
• Das S, Johnson DB. 2019. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer. 7(1):306. doi:10.1186/s40425-019-0805-8.
   PubMed Web of Science ®Google Scholar
• Quach HT, Dewan AK, Davis EJ, Ancell KK, Fan R, Ye F, Johnson DB. 2019. Association of anti-programmed cell death 1 cutaneous toxic effects with outcomes in patients with advanced melanoma. JAMA Oncol. 5(6):906–908. doi:10.1001/jamaoncol.2019.0046.
   PubMed Web of Science ®Google Scholar
• Tumeh PC, Hellmann MD, Hamid O, Tsai KK, Loo KL, Gubens MA, Rosenblum M, Harview CL, Taube JM, Handley N, et al. 2017. Liver metastasis and treatment outcome with anti-pd-1 monoclonal antibody in patients with melanoma and NSCLC. Cancer Immunol Res. 5(5):417–424. doi:10.1158/2326-6066.CIR-16-0325.
   PubMed Web of Science ®Google Scholar
• Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, Hicks M, Puzanov I, Alexander MR, Bloomer TL, et al. 2016. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 375(18):1749–1755. doi:10.1056/NEJMoa1609214.
   PubMed Web of Science ®Google Scholar
• Berner F, Bomze D, Diem S, Ali OH, Fässler M, Ring S, Niederer R, Ackermann CJ, Baumgaertner P, Pikor N, et al. 2019. Association of checkpoint inhibitor-induced toxic effects with shared cancer and tissue antigens in non-small cell lung cancer. JAMA Oncol. 5(7):1043–1047. doi:10.1001/jamaoncol.2019.0402.
   PubMed Web of Science ®Google Scholar
• Cohen JV, Misdraji J, Dougan M, Fadden R, Rubin KM, Lawless A, Reynolds KL, Lawrence DP, Mooradian M, Flaherty K, et al.. 2018. Characterization of immune-related hepatitis (irH) from immune checkpoint inhibitors (ICIs). Journal of Clinical Oncology. 36(15_suppl):3087–13087. doi:10.1200/JCO.2018.36.15_suppl.3087.
   Web of Science ®Google Scholar
• Imoto K, Kohjima M, Hioki T, KurashigeT, KurokawaM, Tashiro S, Suzuki, H, Kuwano A, Tanaka M, Okada S, et al. 2019. Clinical features of liver injury induced by immune checkpoint inhibitors in japanese patients. Can J Gastroenterol Hepatol. 2019:6391712. doi:10.1155/2019/6391712.
   PubMed Web of Science ®Google Scholar
• Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, Dalle S, Schenker M, Chiarion-Sileni V, Marquez-Rodas I, et al. 2017. Adjuvant nivolumab versus ipilimumab in resected stage iii or iv melanoma. N Engl J Med. 377(19):1824–1835. doi:10.1056/NEJMoa1709030.
   PubMed Web of Science ®Google Scholar
• lEggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Lichinitser M, Khattak A, CarlinoMS, et al. 2018. Adjuvant pembrolizumab versus placebo in resected stage iii melanoma. New England Journal of Medicine. 378(19):1789–1801. doi:10.1056/NEJMoa1802357.
   PubMed Web of Science ®Google Scholar
• Pollack MH, Betof A, Dearden H, Rapazzo K, Valentine I, Brohl AS, Ancell KK, Long GV,Menzies AM, Eroglu Z, et al. 2018. Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma. Ann Oncol. 29(1):250–255. doi:10.1093/annonc/mdx642.
   PubMed Web of Science ®Google Scholar
• Simonaggio A, Michot JM, Voisin AL, Le Pavec J, Collins M, Lallart A, Cengizalp G, Vozy A, Laparra A, Varga A, et al. 2019. Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer. JAMA Oncol. 5(9):1310–1317. doi:10.1001/jamaoncol.2019.1022.
   PubMed Web of Science ®Google Scholar
• Santini FC, Rizvi H, Plodkowski AJ, Ni A, Lacouture ME, Gambarin-Gelwan M, Wilkins O, Panora E, Halpenny DF, Long NM, et al. 2018. Safety and efficacy of re-treating with immunotherapy after immune-related adverse events in patients with NSCLC. Cancer Immunol Res. 6(9):1093–1099. doi:10.1158/2326-6066.CIR-17-0755.
   PubMed Web of Science ®Google Scholar